Full length articleComparison of the antinociceptive profiles of morphine and oxycodone in two models of inflammatory and osteoarthritic pain in rat
-
Add time:09/24/2019 Source:sciencedirect.com
Oxycodone and morphine are two opioid drugs commonly used for the treatment of moderate to severe pain. However, their use in the management of noncancer pain remains a controversial issue and, in this respect, the evidence on their effectiveness and safety, particularly in osteoarthritis, is being questioned. In order to analyse their analgesic profile, two different pain models in rats were used: the formalin-induced inflammatory pain and the monosodium iodoacetate (MIA)-induced knee osteoarthritic pain. Drugs were administered systemically (i.p.) and their antinociceptive effect and potency were assessed. In the formalin test, both morphine and oxycodone produced a dose-dependent antinociceptive effect, but oxycodone outdid morphine in terms of effectiveness and potency (nearly two times) in the early (acute nociceptive) as in the late phase (inflammatory). In the osteoarthritis model, both drugs reduced movement–evoked pain (knee-bend test), mechanical allodynia (von Frey test) and heat hyperalgesia (Plantar test). Pretreatment with naloxone and naloxone methiodide reduced morphine and oxycodone effects. Peripheral mu-opioid receptors play a crucial role in the antinociceptive effect of both drugs on movement-evoked pain and heat hyperalgesia, but not on tactile allodynia.The main finding of our study is that oxycodone has a better antinociceptive profile in the inflammatory and osteoarthritic pain, being more effective than morphine at 14 days post-MIA injection (phase with neuropathic pain); it overcame the morphine effect by improving the movement-induced pain, tactile allodynia and heat hyperalgesia.Therefore, oxycodone could be an interesting option to treat patients suffering from knee osteoarthritis when opioids are required.
We also recommend Trading Suppliers and Manufacturers of OXYCODONE HYDROCHLORIDE (cas 124-90-3). Pls Click Website Link as below: cas 124-90-3 suppliers
Prev:Original ArticleMicrobiological and Physicochemical Stability of OXYCODONE HYDROCHLORIDE (cas 124-90-3) Solutions for Patient-Controlled Delivery Systems
Next:Prophylactic vaccination protects against the development of oxycodone self-administration) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ReportSafety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily OXYCODONE HYDROCHLORIDE (cas 124-90-3) Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study10/01/2019
- Research reportOxycodone suppresses the apoptosis of hippocampal neurons induced by oxygen-glucose deprivation/recovery through caspase-dependent and caspase-independent pathways via κ- and δ-opioid receptors in rats09/27/2019
- Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice09/26/2019
- Prophylactic vaccination protects against the development of oxycodone self-administration09/25/2019
- Original ArticleMicrobiological and Physicochemical Stability of OXYCODONE HYDROCHLORIDE (cas 124-90-3) Solutions for Patient-Controlled Delivery Systems09/10/2019
- Original research articlePharmacokinetics of OXYCODONE HYDROCHLORIDE (cas 124-90-3) and three of its metabolites after intravenous administration in Chinese patients with pain09/09/2019
- Case ReportPremedication with fast-acting OXYCODONE HYDROCHLORIDE (cas 124-90-3) hydrate effectively reduced oxaliplatin-induced severe vascular pain09/08/2019
-
Health and Chemical more >


